27 October 2017
This article was written by Yolanda Redrup and originally appeared in the Australian Financial Review on 26 October, 2017.
A new project which aims to improve cancer clinical trials by renowned research body The Garvan Institute is one of 20 initiatives set to receive more than $22.5 million in funding from MTPConnect and industry partners.
The Garvan Institute project will provide access to its genetic profiling platform to enable a clinically accredited tumour genomic test, an analysis platform, and patient-matching capabilities to optimise recruitment and treatment in cancer clinical trials.
Other initiatives to receive backing ranged from programs to boost the clinical trial skills of university graduates to creating a hub to help medtech companies build health solutions, which offers real-life testing for new products and services.
MTPConnect, one of the federal government's six industry growth centres, provided $7.4 million of the funding across the 20 projects, while 200 industry consortium partners made up the remaining $15.2 million.
To read the remainder of the article, please access it on the Australian Financial Review website.